302 results about "ARDS" patented technology

The invention provides methods and means for the inhibition or neutralisation of death receptor / death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and / or the Toll-like receptor family, and / or NOD-like receptor and / or of the signalling induced via these receptors, preferably in combination with each other and / or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

The invention relates to the technical field of biomedical engineering, and discloses an acute respiratory distress syndrome mechanical ventilation adaptive adjustment control system, which comprises a data acquisition module, a signal preprocessing module, a physiological parameter calculation module, a prediction module, a decision and control logic module and the like. Wherein the prediction module predicts a dynamic lung compliance change trend by using a long short-term memory neural network model, and the decision and control logic module generates a ventilation parameter adjustment instruction according to a prediction result and a clinical safety rule. By adopting the technical scheme, the system overcomes the hysteresis of traditional feedback regulation, reduces the risk of breathing machine related lung injury, optimizes oxygenation and carbon dioxide removal efficiency, and provides an accurate, safe and individualized mechanical ventilation treatment scheme.

The invention discloses a prone position ARDS patient death risk prediction system based on interpretable machine learning, which constructs an interpretable machine learning prediction model based on clinical data of an ARDS patient before the ARDS patient receives prone position ventilation treatment, and is used for identifying high-death-risk crowds in an ICU (Intensive Care Unit). According to the method, an optimal prediction model is determined by performing preprocessing and correlation and collinearity screening on original variables, selecting key features by adopting Lasso regression and combining multi-model training and cross validation. On the basis, an SHAP method is introduced to explain a model decision basis, a column graph is constructed, visual expression of a risk assessment result is realized, and clinical understandability and practicability of the model are improved, so that auxiliary support is provided for precise treatment and resource allocation.

The invention relates to the technical field of early warning and evaluation of acute respiratory distress syndromes, in particular to a method for constructing an early warning and evaluation model for acute respiratory distress syndromes. The method comprises the following steps: performing time sequence feature screening on a multi-dimensional heterogeneous database to obtain an optimal time sequence feature set; performing symptom severity quantification on the multi-dimensional heterogeneous database to obtain quantified symptom feature data; performing symptom mutation point time sequence analysis on the quantized symptom feature data to obtain symptom mutation point data; performing symptom interaction influence analysis on the quantized symptom feature data to obtain symptom influence data; performing symptom dynamic feature integration based on the symptom influence data to obtain dynamic symptom features; and performing symptom time sequence feature fusion on the dynamic symptom features and the optimal time sequence feature set to obtain a dynamic symptom feature set. According to the method, the limitation of a traditional model is solved by constructing the hierarchical risk prediction model, and the accuracy and reliability of early warning of the ARDS are improved.

The invention discloses a risk early warning system based on enteral nutrition management of a patient, and belongs to the technical field of medical technology and biomedicine. A risk early warning system based on enteral nutrition management of a patient comprises a patient monitoring module, a score calculation module, a nutrition control module, an early warning notification module, a nutrition scheme adjustment module and a continuous observation and feedback module. The problems that in the prior art, symptoms of critical patients with the acute respiratory distress syndrome are not monitored in time, the regulation efficiency of enteral nutrition supply is low, errors are prone to occurring, and an early warning mechanism is incomplete are solved. By introducing a real-time monitoring and intelligent quantitative evaluation tool, an automatic regulation and control mechanism and multi-level early warning notification and detailed guidance, main problems existing in enteral nutrition management of the severe patient with the acute respiratory distress syndrome at present are effectively solved, and the rehabilitation process and the treatment effect of the patient are remarkably improved.

Methods and compositions are disclosed for treating and preventing cytokine release syndrome (CRS). acute respiratory distress syndrome (CRS), and alveolar capillary injury (ACI) in a subject.

The present invention relates to an inhibitor of C5a activity and an inhibitor of IL-6 activity for use in the treatment of infectious pneumonia and infectious acute respiratory distress syndrome (ARDS). In further aspects administration regimes and kit of parts are referred to.

The invention belongs to the technical field of biomedicine, and particularly relates to application of GPR161 as an acute distress syndrome diagnostic marker and a therapeutic target. Experiments prove that the expression level of GPR161 in peripheral blood mononuclear cells of a patient with the acute respiratory distress syndrome is remarkably increased, and the expression quantity of the GPR161 is positively correlated with the severity of the disease, so that the GPR161 gene or GPR161 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of the acute respiratory distress syndrome; a reagent for inhibiting GPR161 gene expression or protein activity can be used for preparing a medicine for treating the acute respiratory distress syndrome. The invention provides a new strategy for diagnosis, monitoring and targeted drug development of ARDS, and has important clinical application value.

The invention relates to the technical field of bioinformatics, in particular to a method for typing acute respiratory distress syndrome biological subtypes. The method comprises the following steps: a) acquiring multi-omics data and carrying out standardized preprocessing; the multi-omics data comprises transcriptomics data, proteomics data and metabonomics data of a biological sample source; b) constructing a similarity network of each group by using a similarity fusion network (SNF), and obtaining a uniform sample similarity matrix through multi-group network fusion and iteration; multiple collaborative principal component analysis (MCIA) is adopted to carry out dimension reduction on multi-omics data so as to realize visualization of a clustering result; carrying out multi-omics joint discrimination modeling under the guidance of SNF clustering by using a data integration analysis (DIABLO) method so as to identify key feature variables; and carrying out biological subtype classification based on the clustering result of the steps.

Provided herein are modulators of a long noncoding transcript, pharmaceutical compositions comprising the modulator, and kits comprising the modulator. Also provided herein are methods of modulating a long noncoding transcript in a subject in need thereof. Further provided here are methods of preventing, alleviating, or treating pulmonary fibrosis or inflammation induced or associated with ARDS in a subject in need thereof.

The invention provides a synthesis method of a novel inhalable liposome and an application of the novel inhalable liposome in ARDS (arterial thrombosis syndrome) treatment, and the synthesis method comprises the following steps: firstly, mixing DSPE-PEG2K-TK-NHS and tocilizumab (TCZ: Tocilizumab) to form a lead compound DSPE-PEG2K-TK-TCZ; the preparation method comprises the following steps: dissolving DPPC, cholesterol, DSPE-TK-PEG2k and FG4592 in 5mL of chloroform, carrying out reduced pressure evaporation in a sample bottle to form a film, and adding 3mL of deionized water to prepare Lip-coated RF; and then stirring and incubating the DSPE-PEG2K-TK-TCZ and the Lip (at) RF, so as to form the Lip (at) RFT. As a functional nano-material with ultra-small size, good biocompatibility, excellent ROS removal capability and ROS responsive drug release, the nano-material is used for treating ARDS. The invention has the advantages that: the Lip-coated RFT relieves lung oxidative stress, inflammatory response, protein permeability and histological severity in the LPS-induced mouse ALI model. Therefore, Lip at RFT can be used as a new way for treating ARDS. Aerosol inhalation of Lip-coated RFT can effectively improve the severity of ARDS.

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

Apparatus and methods are described for continuous and non-invasive detection of (1) respiratory effort, and (2) cellular oxygen requirement compared to cellular oxygen supply. The apparatus is configurable for remote patient care and configured to monitor one or more of sleep disordered breathing, hypertension, heart failure, pneumonia, asthma, chronic obstructive pulmonary disease (COPD), respiratory distress syndrome (RDS) in premature infants, and acute respiratory distress syndrome (ARDS) in children and adults. Additionally, the device is configurable to control delivery of therapy.

The invention discloses an imitated intercorial nano preparation for treating acute respiratory distress syndrome, and belongs to the technical field of biological medicine. The internalized nano preparation comprises an active component, a liposome phospholipid bilayer and a target head, wherein the active component consists of an ROS (reactive oxygen species) removing drug and an anti-inflammatory drug. According to the invention, efficient and accurate targeting of the nano-preparation is realized by innovatively applying an imitated interment effect, an apoptotic cell marker is modified on the surface of the liposome, and an'eat me 'signal is released to simulate a natural biological process that macrophages clear apoptotic cells to be recognized and swallowed by alveolar macrophages, so that efficient and specific targeting is realized, and the targeting effect of the nano-preparation is improved. Meanwhile, up-regulation of PS receptor expression of macrophages at the inflammation part further enhances the targeting effect, and a new way is provided for efficient delivery of acute respiratory distress syndrome medicine preparations and remodeling of pathological microenvironment.

The invention discloses an application of sIL-2R alpha as a marker in a product for early prediction of acute respiratory distress syndrome. The product for early predicting the acute respiratory distress syndrome comprises a reagent or a medicine for detecting the expression level of sIL-2R alpha in a patient with the acute respiratory distress syndrome. The sIL-2R alpha is used as a biomarker, and experiments prove that the sIL-2R alpha level of the plasma of the ARDS patient is obviously higher than that of a patient without ARDS in the plasma of the ARDS patient. By detecting the sIL-2R alpha level of plasma or serum of an ARDS patient, the ARDS occurrence risk is predicted in an early stage, so that individualized intervention treatment is given, the occurrence rate of ARDS can be reduced, and the kit has important clinical application value for improving prognosis of the ARDS patient.

The invention relates to a class of small molecule inhibitors of GPR68 / OGR1, a proton-sensing / stretch-sensing / sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

The invention discloses an intelligent diagnosis and typing method for pneumonia-related ARDS, and relates to the technical field of intelligent diagnosis and typing methods for ARDS, and the method comprises the steps: employing a data preprocessing method to carry out cleaning and standardization processing on pneumonia patient clinical data from MIMIC-IV and eICU databases, and obtaining a standardized data set; a correlation weight algorithm is adopted to screen 52 candidate variables in the standardized data set, and 18 key prediction factors are obtained; carrying out model training on the screened key predictive factors by adopting a machine learning stacking method to obtain a pneumonia-related ARDS diagnosis model; performing clustering analysis on the clinical data of the pneumonia-related ARDS patients by adopting a k-means clustering method, and dividing the patients into three clinical phenotypes based on nine input factors to obtain a subtype classification result; verifying a subtype classification result by adopting a random forest method to obtain a clinical subtype prediction model with high accuracy; and integrating and deploying the diagnosis model and the subtype classification model by adopting a webpage application program.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention discloses a biomarker combination for evaluating the illness state or prognosis of ARDS in the technical field of intensive care medicine, the biomarker combination comprises miR-21-5P and lncRNAgad7, and the biomarker combination can be used for predicting and evaluating the illness state or prognosis of ARDS so as to improve the accuracy of evaluating the illness state or prognosis of ARDS.

The invention discloses application of ubiquitin specific protease USP4 in treatment of acute lung injury / acute respiratory distress syndrome. The GEO database analysis finds that USP4 is increased in patients with acute respiratory distress syndrome; the expression level of USP4 is increased by stimulating human neutrophils in vitro with LPS, and experiments prove that the USP4 inhibitor Vialinin A can effectively treat acute lung injury and effectively improve the survival rate of mice; acute lung injury can be effectively relieved by using adenovirus to inhibit expression of USP4 in lung; the USP4 defect of the hematopoietic system can effectively relieve acute lung injury. The application of the USP4 serving as the target spot in screening the medicine for treating the acute lung injury or the acute respiratory distress syndrome is provided for the first time, a new target spot is provided for treating the acute lung injury or the acute respiratory distress syndrome, and a new treatment strategy is provided for clinical treatment.

A use of a compound represented by formula I, or a cis-trans isomer, enantiomer, diastereomer, racemate, solvate, hydrate, pharmaceutically acceptable salt or prodrug thereof in the preparation of a drug for preventing, relieving, assisting in treating, or treating lung injury. Upon verification, administration of the compound represented by formula I can significantly reduce proinflammatory cytokines, i.e., tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6), of a rat model of acute lung injury, reduce the infiltration of inflammatory cells (comprising monocytes / macrophages, lymphocytes, and neutrophils) in lung tissues, relieve pathological injury of the lung tissues, improve the lung function, and increase the survival rate of comorbidities of acute lung injury. The compound represented by formula I can be used for preventing, relieving, assisting in treating, or treating lung injury, especially acute lung injury or comorbidities thereof, or acute respiratory distress syndrome or comorbidities thereof.

In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID-19-induced acute respiratory distress syndrome (ARDS) and requires supplemental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.

The invention belongs to the technical field of medicines, and particularly discloses application of binding molecules of actin binding protein LASP1 in prevention and treatment of acute respiratory distress syndrome (ARDS). According to the invention, the LASP1-loaded nanoparticles are constructed, so that the problems that the drug is difficult to penetrate and easy to remove and degrade and the ARDS is difficult to treat are solved. According to the invention, through intranasal instillation of the HA-DA / BP / LASP1 nanoparticles, the level of inflammatory factors can be reduced, the alveolar epithelial barrier structure and function can be repaired, and the death rate of ARDS model mice can be reduced.

The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and / or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19 / cytokine release syndrome therapeutics-prophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-(R)-3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methylpropanoic acid—as a racemic mixture or separately, as the “R” enantiomer), compound 4 (3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-propanoic acid) and LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neo-natal / pediatric ARDS), including meconium aspiration syndrome and other disease states and conditions are also disclosed.

The invention provides a neonatal acute respiratory distress syndrome antenatal prediction model, which is characterized in that 15 key variables for predicting neonatal acute respiratory distress syndrome are screened out by using an LASSO regression algorithm according to perinatal high-risk factors; and taking the key variables as input, taking the neonatal acute respiratory distress syndrome as output, and training by using a BP neural network to obtain the neonatal acute respiratory distress syndrome antenatal prediction model. According to the method, personalized early prediction of the NARDS can be realized, and the possibility of occurrence of the neonatal acute respiratory distress syndrome can be predicted before a fetus is born; in the prediction process, the examination result can be obtained only by inputting various existing examination data into the prediction model, the method is simple and easy to operate, visual, reliable and rapid, evaluation can be conducted at any time, and the requirements for professional knowledge of medical staff and hospital instruments and equipment are low.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and / or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and / or SARS-CoV-2 / COVID-19, and influenza virus infections, optionally, H1N1 and / or H5N1.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.